Navigation Links
Anesiva Appoints Daniel Janney to Board of Directors
Date:2/8/2008

its leveraged buyout/private equity group. Mr. Janney received a B.A. in History from Georgetown University and an M.B.A. from the Anderson School at the University of California, Los Angeles.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Anesiva Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or a
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
2. Anesiva Announces Completion of Common Stock Offering
3. Anesiva Raises $45 Million in Common Stock Offering
4. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
7. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
11. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... the "Genotyping Market by Technology, Application & by ... their offering. The global genotyping market is ... Billion in 2015, at a CAGR of 22.3% during ... Market growth will be attributed to the availability of ...
(Date:6/2/2015)... , June 2, 2015   BioClinica ® , ... provider, today announced that David Peters , an ... Executive Vice President and Chief Financial Officer (CFO) and ... Peters brings more than 25 years of financial ... "David has extensive and deep knowledge in all areas ...
(Date:6/2/2015)...  Alere Inc. (NYSE: ALR ), a ... House Antibiotic Stewardship Forum today to announce a ... the President,s National Action Plan to Combat Antibiotic-Resistant ... measurable goals and objectives over the next five ... protect their patients through antibiotic stewardship, slow the ...
(Date:6/2/2015)... New Orleans, LA (PRWEB) June 02, 2015 ... of custom gene synthesis to improve protein expression, announced ... The board includes six executives and entrepreneurs with a ... and software industries. , The team includes: , ... Startup Fund: , Roussel has a background in technology ...
Breaking Biology Technology:Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2BioClinica Names David Peters New Chief Financial Officer 2Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3
... Abstract , Using high ... with differing surface treatment procedures and carbon content levels , ... , Introduction , ... made commercially available that offer optimized properties for select , ...
... , Contaminations of cell cultures show ... production industry. The attention turns here particularly to the prevention , ... or fungi. For companies , that ... a main focus., Endotoxins ...
... Key words: Amino Acids, RP-HPLC, Precolumn derivatisation, o-Phthalaldehyde ... Introduction: , ... significantly absorb light in the UV/visible spectrum. In order ... step in which the amino acids react with a ...
Cached Biology Technology:TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 2TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 3Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 2Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 3Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 4Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 5Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 6Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 7ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 2ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 3
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... 2015  Through a well-rounded UAS delegation representing private industry, ... strong showing at AUVSI,s Unmanned 2015 conference last week in ... Ohio,s UAS industry met with over 200 hundred ... along the UAS ecosystem. "Our message is ... for Aerospace Rich Knoll . "If you want to ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Hospital have discovered a new genetic disease that can lead ... bile is missing, the liver cells are exposed to the ... a transformation of liver cells into connective tissue with a ... the cases of liver cirrhosis of unknown origin and open ...
... Meyskens, Jr., M.D., one of the "fathers" of ... to receive the seventh annual American Association for ... in Cancer Prevention Research. The award is ... to the field of cancer prevention research in ...
... Jewish Health have identified a simple gene-based blood test ... response to therapy than current tests. The test, a ... and help clear a backlog of promising medications now ... the results of a small "proof-of-principal" trial in the ...
Cached Biology News:Toxic bile damages the liver 2Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... data analysis , Automatic grid, subgrid and spot ... template assignment , ... Extensive background and signal options to optimize, ... results , Characterize ...
... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
Biology Products: